David Scheinberg's Bio
David A. Scheinberg, M.D., Ph.D. is currently Vincent Astor Chair, and Chairman, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute. He also founded and Chairs the Experimental Therapeutics Center, and founded and was Chair of the Nanotechnology Center from 2010 to 2014. He is additionally Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC. He is a founder and Director of the Therapeutics Discovery Institute, a non profit drug discovery corporation formed with Weill Cornell Medical College, Rockefeller University and Sloan Kettering Institute. From 1992 until 2003, he was Chief of the Leukemia Service at Memorial Hospital. He has been elected into the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, The Emil J. Freireich Award, Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. He is an advisor to charitable foundations and cancer centers and sits on the Boards of Directors of public and private biotech companies. Dr. Scheinberg is a physician-scientist, specializing in the care of patients with leukemia and also investigating new therapeutic approaches to cancer, both in the hospital and in the laboratory. The focus of his research is on the discovery and development of novel, specific immuno-therapeutic agents. This includes monoclonal antibodies that target cell surface or intracellular proteins of cancers, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, and targeted nano-devices for selective cell kill, and therapeutic vaccines targeting the oncogene products that cause the cancers. Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, which include the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 250 papers, chapters, or books in these fields.